Evidence map›Paper›PMID 28177437›Full record

GuidelineAnnals of oncology : official journal of the European Society for Medical Oncology2017

3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).

F Cardoso, A Costa, E Senkus, M Aapro, F André, C H Barrios, J Bergh, G Bhattacharyya, L Biganzoli, M J Cardoso and 35 more

Erratum issued Registry-linked trialAbstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Annals of oncology : official journal of the European Society for Medical Oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04012918 (Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study), which is not on this map. Cited by 210 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
210citing papers in PubMed, 14 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04012918 phase2unknown statusnot on this mapstarted 2018, after this paper: background citation

Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study (CONCEPT Trial)

TypeinterventionalSponsorAin Shams UniversityRan2018 to 2021Enrolled124ConditionsMetastatic Breast CancerArmsCapecitabine plus aromatase inhibitor, A.I.
3 · Its place in the literature

Who cites it

210 citing papers in PubMed, 14 syntheses or guidelines pooled it.

  1. Guideline
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020
    Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Trial
  20. Trial

150 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

45 authors.

F CardosoEuropean School of Oncology & Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal.
A CostaEuropean School of Oncology, Milan, Italy and European School of Oncology, Bellinzona, Switzerland.
E SenkusDepartment of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland.
M AaproBreast Center, Genolier Cancer Center, Genolier, Switzerland.
F AndréDepartment of Medical Oncology, Gustave Roussy Institute, Villejuif, France.
C H BarriosDepartment of Medicine, PUCRS School of Medicine, Porto Alegre, Brazil.
J BerghDepartment of Oncology/Radiumhemmet, Karolinska Institutet & Cancer Center Karolinska and Karolinska University Hospital, Stockholm, Sweden.
G BhattacharyyaDepartment of Medical Oncology, Fortis Hospital, Kolkata, India.
L BiganzoliMedical Oncology Department, Hospital of Prato, Prato, Italy.
M J CardosoBreast Unit, Champalimaud Clinical Center, Lisbon, Portugal.
L CareyDepartment of Hematology and Oncology, UNC Lineberger Comprehensive Cancer Center.
D Corneliussen-JamesMETAvivor Research and Support, Annapolis, USA.
G CuriglianoDivision of Experimental Therapeutics, European Institute of Oncology, Milan, Italy.
V DierasDepartment of Medical Oncology, Institut Curie, Paris, France.
N El SaghirNK Basile Cancer Institute Breast Center of Excellence, American University of Beirut, Beirut, Lebanon.
A EniuDepartment of Breast Tumors, Cancer Institute 'I. Chiricuta', Cluj-Napoca, Romania.
L FallowfieldBrighton & Sussex Medical School, University of Sussex, Falmer, UK.
D FenechBreast Care Support Group, Europa Donna Malta, Mtarfa, Malta.
P FrancisDivision of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia.
K GelmonBC Cancer Agency, Vancouver Cancer Centre, Vancouver, Canada.
A GennariDepartment of Medical Oncology, Galliera Hospital, Genoa, Italy.
N HarbeckBrustzentrum der Universitat München, Munich, Germany.
C HudisBreast Medicine Service, Memorial Sloan-Kettering Cancer Centre, New York, USA.
B KaufmanSheba Medical Center, Tel Hashomer, Israel.
I KropDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston.
M MayerAdvanced Breast Cancer.org, New York, USA.
H MeijerDepartment of Radiation Oncology, Radvoud University Medical Center, Nijmegen, The Netherlands.
S MertzMetastatic Breast Cancer Network US, Inversness, USA.
S OhnoBreast Oncology Centre, Cancer Institute Hospital, Tokyo, Japan.
O PaganiOncology Institute of Southern Switzerland and Breast Unit of Southern Switzerland, Bellinzona, Switzerland.
E PapadopoulosEuropa Donna, Nicosia, Cyprus.
F PeccatoriEuropean School of Oncology, Milan, Italy and Bellinzona, Switzerland.
F Penault-LlorcaJean Perrin Centre, Comprehensive Cancer Centre, Clermont Ferrand, France.
M J PiccartDepartment of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
J Y PiergaDepartment of Medical Oncology, Institut Curie-Université Paris Descartes, Paris, France.
H RugoDepartment of Medicine, Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco.
L ShockneyDepartment of Surgery and Oncology, Johns Hopkins Breast Center, Baltimore.
G SledgeIndiana University Medical CTR, Indianapolis.
S SwainLombardi Comprehensive Cancer Center, Georgetown University, Washington, USA.
C ThomssenDepartment of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle an der Saale, Germany.
A TuttBreakthrough Breast Cancer Research Unit, King's College London and Guy's and St Thomas's NHS Foundation Trust, London, UK.
D VorobiofSandton Oncology Centre, Johannesburg, South Africa.
B XuDepartment of Medical Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
L NortonBreast Cancer Program, Memorial Sloan-Kettering Cancer Centre, New York.
E WinerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Breast NeoplasmsBreast Neoplasms, MaleFemaleHumansMaleObservational Studies as TopicRandomized Controlled Trials as Topic

Identifiers

PMID28177437
PMCPMC5378224

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.